ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
125.924,19
-1,12%
S&P 500
5.035,69
-1,57%
US Dollar vs BRL
5,1958
0,01%
Bitcoin
57.622,84
-4,91%
Brent Oil
85,06
-0,97%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Regeneron Pharmaceuticals Inc (REGN)

  7. Regeneron Pharmaceuticals Inc (REGN) Notícias

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN
DataHoraFonteTítuloCódigoCompanhia
29/04/202408:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/04/202408:00GlobeNewswire Inc.Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple DiseasesNASDAQ:REGNRegeneron Pharmaceuticals Inc
24/04/202411:05GlobeNewswire Inc.Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCONASDAQ:REGNRegeneron Pharmaceuticals Inc
22/04/202418:54GlobeNewswire Inc.Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/04/202408:18IH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/04/202408:24IH Market NewsCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’ AI Chip, and More NewsNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/04/202417:00GlobeNewswire Inc.Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/04/202417:05GlobeNewswire Inc.Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024NASDAQ:REGNRegeneron Pharmaceuticals Inc
25/03/202408:00GlobeNewswire Inc.Regeneron Provides Update on Biologics License Application for OdronextamabNASDAQ:REGNRegeneron Pharmaceuticals Inc
13/03/202400:55PR Newswire (US)High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical OptimizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
11/03/202408:00GlobeNewswire Inc.Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High CholesterolNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/03/202409:00GlobeNewswire Inc.EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The LancetNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/03/202418:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
01/03/202418:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
23/02/202403:00GlobeNewswire Inc.Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 InflammationNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/02/202409:00GlobeNewswire Inc.Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority ReviewNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/02/202402:59GlobeNewswire Inc.Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)NASDAQ:REGNRegeneron Pharmaceuticals Inc
09/02/202420:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/02/202418:01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:REGNRegeneron Pharmaceuticals Inc
06/02/202418:05GlobeNewswire Inc.Regeneron Announces Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/02/202411:16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202409:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:30GlobeNewswire Inc.Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
02/02/202408:00GlobeNewswire Inc.Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple MyelomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202411:25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:REGNRegeneron Pharmaceuticals Inc
30/01/202409:00GlobeNewswire Inc.Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical ProgramsNASDAQ:REGNRegeneron Pharmaceuticals Inc
25/01/202416:29GlobeNewswire Inc.Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)NASDAQ:REGNRegeneron Pharmaceuticals Inc
24/01/202414:05PR Newswire (US)Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in AwardsNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/01/202409:00GlobeNewswire Inc.Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot InvolvementNASDAQ:REGNRegeneron Pharmaceuticals Inc
08/01/202409:30PR Newswire (Canada)Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple CountriesNASDAQ:REGNRegeneron Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:REGN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
TECN3
TECHNOS ON
BOV
BLAU3
Blau Farmaceutica ON
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados